KEY-13

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameKEY-13
Drug Alias Nametriple reuptake inhibitor (Jazz Pharmaceuticals)triple monoamine reuptake inhibitor (Jazz Pharmaceuticals)KEY-13
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitors
TargetsNorepinephrine transporterSerotonin transporter
Therapy Area/IndicationsDepression
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJazz Pharmaceuticals Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJazz Pharmaceuticals Plc
Active IndicationsN/A
Inactive IndicationsDepression

Other Information

ATC CodeN/A
Related LinksN/A